Mapping airway epithelial cell-immune cell interactions in lung health and disease
Active Cooperative Agreement Awarded Last action
- Award ID
- U01HL175384
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,345,061
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 43% complete
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
Description
- Abstract
- Asthma and chronic obstructive pulmonary disease (copd) are inflammatory diseases that affect the airways and, together, are the largest causes of disability and mortality from chronic respiratory disorders worldwide. At the heart of the pathophysiology of both diseases is altered airway epithelial cell (AEC)-immune cell interactions with aberrant activation of innate and adaptive immunity, notable for the accumulation of activated airway t cells and b cells. IT is thought that pathogenic AEC-myeloid cell-CD4+ t cell circuits underlie the pathophysiology of asthma, while AEC-myeloid cell-CD8+ t cell circuits predominate in copd, but the diversity of aecs and immune cells involved are only now receiving scrutiny. In particular, rare AEC subtypes, including tuft, hillock, microfold, and neuroendocrine cells, are known to secrete immune cell-active mediators, but their role in human disease has not been established. Additionally, airway cellular structures such as hillock islands and inducible bronchial associated lymphoid tissue (ibalt) are immunologically active in asthma and copd, but their role in disease pathogenesis is unknown. Furthermore, studies suggest that the t cell and b cell response to specific antigens, whether host-, allergen- and/or microbe-derived, may be important in the pathophysiology of asthma and copd, but current efforts have not deeply characterized the specificity and function of the adaptive immune cells that accumulate in airways, nor their interactions with specific AEC populations. Our overall objective is to comprehensively define the signaling and spatial relationships of common and rare AEC cell types, airway structures such as the hillock and ibalt, and specific airway immune cell populations in asthma and copd to ultimately define therapeutic approaches that precisely target disease-specific mechanisms. Our group has established protocols and methods for safely sampling asthmatic and copd airways from well-defined patient cohorts and for obtaining tissue from diseased lung explants and donor lungs with asthma that were rejected for transplants. Using these methods, we have characterized the cellular profiles of AEC and immune cells in healthy, asthmatic, and copd lungs and have defined some of the critical AEC-immune cell interactions within the airways of these subjects. We hypothesize that aberrant AEC-immune cell interactions involving AEC subtypes as well as airway structural features such as hillock islands and ibalt drive chronic immune activation in the airway, which ultimately promotes activation of airway-resident memory t cells and b cells, thus establishing a persistent inflammatory state that shapes the clinical course of asthma and copd. The specific aims are 1) to determine and compare the transcriptional and spatial profiles of AEC-immune cell interactions in asthma and copd, and 2) to define t cell and b cell receptor repertoires in the airways of patients with asthma and copd. A deeper understanding of AEC-immune cell interactions in asthma and copd will help define pathogenic mechanisms of each disease and may identify disease-specific therapeutic targets.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $765,687 | |
| Amendment | $781,312 | |
| Original award | $798,062 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Broad Institute, Inc. | $829,044 |
Quick answers
Who received award U01HL175384?
U01HL175384 was awarded to The General Hospital Corporation by National Heart Lung and Blood Institute (National Institutes of Health) on September 1, 2024.
How much is award U01HL175384 worth?
$2,345,061 has been obligated on U01HL175384.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award